Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

Bone Marrow Transplantation

Volumn 34, Issue 6, 2004, Pages 485-490

  Kumar, S ^a   Lacy, M Q ^a   Dispenzieri, A ^a   Rajkumar, S V ^a   Fonseca, R ^a   Geyer, S ^a   Allmer, C ^a   Witzig, T E ^a   Lust, J A ^a   Greipp, P R ^a   Kyle, R A ^a   Litzow, M R ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autologous transplantation; Dexamethasone; Induction therapy; Multiple myeloma

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; MELPHALAN; MITOXANTRONE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL OBSERVATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 4644231761     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704633     Document Type: Article

References (36)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med 1983; 308: 314-316.
3. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657-1664.
4. Alexanian R, Bonnet J, Gehan E et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382-389.
5. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-824.
6. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
8. Blade J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845-849.
9. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
10. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
11. Attal M, Harousseau J, Facon T et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the 'Intergroupe Francophone du Myelome' (IFM 94). Blood 2002; 100 (Abstr. #7).
12. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol 1999; 16: 245-254.
13. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
14. Alexanian R, Dimopoulos MA, Delasalle KB et al. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 118-121.
15. Kumar S, Lacy MQ, Dispenzieri A et al. Autologous peripheral blood stem cell transplantation for primary refractory multiple myeloma. Blood 2002; 100: 432a.
16. Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
17. Samson D, Gaminara E, Newland A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2: 882-885.
18. Segeren CM, Sonneveld P, van der Holt B et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127-130.
19. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11.
20. Friedenberg WR, Kyle RA, Knospe WH et al. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991; 36: 171-175.
21. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-890.
22. Egerer G, Hegenbart U, Salwender H et al. Outpatient treatment of multiple myeloma with a combination of vincristine, adriamycin and dexamethasone. Support Care Cancer 2001; 9: 380-385.
23. Jackson DV, Case LD, Pope EK et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol 1985; 3: 1508-1512.
24. Alberts DS, Salmon SE. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother Rep 1975; 59: 345-350.
25. Alberts AS, Falkson G, Rapoport BL, Uys A. A phase II study of idarubicin and prednisone in multiple myeloma. Tumori 1990; 76: 465-466.
26. Alberts DS, Balcerzak SP, Bonnet JD, Stephens RL. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. Cancer Treat Rep 1985; 69: 1321-1323.
27. Case Jr DC, Ervin TJ, Gams R et al. Phase I-II study of epirubicin in multiple myeloma. Cancer Res 1988; 48: 6246-6248.
28. Chisesi T, Capnist G, de Dominicis E, Dini E. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol 1988; 24: 681-684.
29. Sumpter K, Powles RL, Raje N et al. Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma. Leuk Lymphoma 1999; 35: 593-597.
30. Rodjer S, Nilsson B, Westin J. Do anthracyclines have a role in the therapy of multiple myeloma? Hematol J 2000; 1: 422-426.
31. Hendler M, Corrado C, Lastiri F et al. Randomized clinical trial comparing melphalan-methyl prednisolone (MP) versus melphalan-methylprednisolone-adriamycin (MPA) in newly diagnosed patients with multiple myeloma. A GATLA study. VII International Multile Myeloma Workshop 1999. Stockholm, 1999 (Abstr. P 50).
32. Majolino I, Vignetti M, Meloni G et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica 1999; 84: 844-852.
33. Alexanian R, Weber D, Delasalle K et al. Value of intensive therapy supported by autologous stem cells (IT+ASCT) for primary resistant multiple myeloma. Blood 2002; 100 (Abstr. #672).
34. Anagnostopoulos A, Aleman A, Williams P et al. Autologous stem cell transplantation (ASCT) after nonmyelosuppressive induction therapy with dexamethasone alone is safe and effective for newly diagnosed multiple myeloma (MM) pts who receive high dose chemotherapy (HDC). Blood 2001; 98 (Abstr. # 2858).
35. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
36. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.